We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BXCL501

News List

BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II drugs
May 24, 2021
BioXcel today announced that FDA has accepted for filing NDA for BXCL501,orally dissolving thin film formulation of dexmedetomidine,for the acute treatment of agitation associated with schizophrenia and Bipolar disorders I and II
BioXcel’s agitation drug gets FDA Fast Track pharmaphorum
December 29, 2018
The FDA has granted Fast Track Designation to BioXcel Therapeutics’ BXCL501 for the treatment of acute agitation resulting from neurological and psychiatric disorders like Alzheimer’s and schizophrenia.